A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy And Safety Study Of Povorcitinib In Participants With Prurigo Nodularis
Posted Date: Nov 18, 2024
- Investigator: Alan Fleischer
- Specialties:
- Type of Study: Drug
The purpose of this study is to evaluate the effect of a new drug (povorcitinib) on itch and skin lesions in participants with PN.
Criteria:
Participants Must Be 18 To 75 Years Old, With A Diagnosis Of Prurigo Nodularis Who Suffer From Severe Itching And Have Tried And Failed Treatment With Topical Medication.
Keywords:
Prurigo Nodularis, Nodules Or Bumps, Sever Itching
For More Information:
Jordan Sambrookes
(513) 475-7631
perryj8@ucmail.uc.edu